$0.66
5.50% today
Nasdaq, Apr 04, 10:16 pm CET
ISIN
US8006771062
Symbol
SGMO
Sector
Industry

Sangamo Therapeutics, Inc. Stock price

$0.66
-0.20 23.64% 1M
-0.12 15.94% 6M
-0.36 35.64% YTD
+0.08 14.23% 1Y
-5.55 89.43% 3Y
-6.11 90.30% 5Y
-14.24 95.59% 10Y
Nasdaq, Closing price Fri, Apr 04 2025
+0.03 5.50%
ISIN
US8006771062
Symbol
SGMO
Sector
Industry

Key metrics

Market capitalization $139.84m
Enterprise Value $128.49m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.22
P/S ratio (TTM) P/S ratio 2.42
P/B ratio (TTM) P/B ratio 5.82
Revenue growth (TTM) Revenue growth -67.20%
Revenue (TTM) Revenue $57.80m
EBIT (operating result TTM) EBIT $-99.13m
Free Cash Flow (TTM) Free Cash Flow $-67.41m
Cash position $41.92m
EPS (TTM) EPS $-0.52
P/E forward negative
P/S forward 1.82
EV/Sales forward 1.67
Short interest 12.94%
Show more

Is Sangamo Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Sangamo Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Sangamo Therapeutics, Inc. forecast:

5x Buy
71%
2x Hold
29%

Analyst Opinions

7 Analysts have issued a Sangamo Therapeutics, Inc. forecast:

Buy
71%
Hold
29%

Financial data from Sangamo Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
58 58
67% 67%
100%
- Direct Costs 9.36 9.36
54% 54%
16%
48 48
69% 69%
84%
- Selling and Administrative Expenses 23 23
35% 35%
39%
- Research and Development Expense 116 116
50% 50%
200%
-90 -90
5% 5%
-155%
- Depreciation and Amortization 9.36 9.36
54% 54%
16%
EBIT (Operating Income) EBIT -99 -99
13% 13%
-172%
Net Profit -99 -99
62% 62%
-172%

In millions USD.

Don't miss a Thing! We will send you all news about Sangamo Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sangamo Therapeutics, Inc. Stock News

Positive
Seeking Alpha
about 3 hours ago
Sangamo Therapeutics, Inc.'s deal with Eli Lilly to develop genomic medicines for CNS using the STAC-BBB AAV capsid brings in an $18M upfront payment and the potential to earn $1.4B in milestone payments. The Fabry Disease gene therapy program, with phase 1/2 STAAR study data expected in 1H 2025, is a major near-term catalyst for investors to keep an eye on. Positive eGFR slope data could lead ...
Neutral
Business Wire
one day ago
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES CAPSID LICENSE AGREEMENT WITH LILLY TO DELIVER GENOMIC MEDICINES FOR DISEASES OF THE CENTRAL NERVOUS SYSTEM.
Neutral
Seeking Alpha
18 days ago
Sangamo Therapeutics, Inc. (NASDAQ:SGMO ) Q4 2024 Earnings Conference Call March 17, 2025 4:30 PM ET Company Participants Louise Wilkie - Vice President, Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Nathalie Dubois-Stringfellow - Chief Development Officer Prathyusha Duraibabu - Chief Financial Officer Conference Call Participants Luis Santos - H.C. Wain...
More Sangamo Therapeutics, Inc. News

Company Profile

Sangamo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases. It also offers complementary technology platforms such as gene therapy, ex vivo cell therapy, in vivo genome editing, and in vivo genome regulation. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Brisbane, CA.

Head office United States
CEO Alexander Macrae
Employees 183
Founded 1995
Website www.sangamo.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today